Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel
NYSEAMERICAN:OGEN

Oragenics Q4 2025 Earnings Report

Oragenics logo
$0.53 -0.01 (-1.85%)
Closing price 07/22/2026 04:10 PM Eastern
Extended Trading
$0.53 0.00 (-0.19%)
As of 07/22/2026 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings History

Oragenics EPS Results

Actual EPS
$0.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Q4 2025
Date
3/16/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics (NYSEAMERICAN:OGEN) Stock Price Down 1.5% - Here's Why
July 21 at 2:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30911479
Oragenics Appoints New Chief Financial Officer and Leader
July 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OGEN/pressreleases/3172047/oragenics-appoints-new-chief-financial-officer-and-leader/
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
 |  Profits Run (Ad)
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323198/0/en/oragenics-achieves-full-activation-of-australian-phase-iia-trial-network-all-three-sites-now-enrolling.html
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oragenics-present-sidoti-micro-cap-124500288.html
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297513/0/en/oragenics-to-present-at-sidoti-s-micro-cap-virtual-investor-conference-may-20-21.html
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSEAMERICAN:OGEN) is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications.

Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN.

Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.

View Oragenics Profile
Earnings Tools